Compare
InMode Ltd. vs TransMedics Group, Inc. vs Axogen, Inc. vs Outset Medical, Inc.
| Latest fiscal year | InMode Ltd. INMD | TransMedics Group, Inc. TMDX | Axogen, Inc. AXGN | Outset Medical, Inc. OM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $370.50M | $605.49M | $225.21M | $119.48M |
| Revenue growth (YoY) | -6.2% | +37.1% | +20.2% | +5.1% |
| Gross margin | 78.5% | 59.9% | 74.3% | 39.1% |
| Operating margin | 23.0% | 17.9% | -3.5% | -55.8% |
| Net margin | 25.3% | 31.4% | -7.0% | -68.3% |
| Net income | $93.83M | $190.29M | -$15.70M | -$81.65M |
| EPS (Diluted) | $1.43 | $4.87 | -$0.34 | -$5.37 |
| Operating cash flow | $85.26M | $192.84M | $812.0K | -$46.33M |
| Free cash flow | $84.28M | $133.59M | -$2.93M | -$47.12M |
| Cash & equivalents | $302.54M | n/a | $35.55M | $35.01M |
| Total assets | $766.43M | $1.07B | $221.69M | $264.50M |
| Total liabilities | $83.23M | $595.27M | $92.84M | $137.54M |
| Shareholders' equity | $683.20M | $473.10M | $128.85M | $126.95M |
| Return on year-end equity | 13.7% | 40.2% | -12.2% | -64.3% |
| Shares outstanding | 63.36M | 34.27M | 47.20M | 18.17M |
Revenue, most recent five fiscal years
| Fiscal year | InMode Ltd. | TransMedics Group, Inc. | Axogen, Inc. | Outset Medical, Inc. |
|---|---|---|---|---|
| Latest | $370.50M Ended 2025-12-31 | $605.49M Ended 2025-12-31 | $225.21M Ended 2025-12-31 | $119.48M Ended 2025-12-31 |
| 1 year earlier | $394.82M Ended 2024-12-31 | $441.54M Ended 2024-12-31 | $187.34M Ended 2024-12-31 | $113.69M Ended 2024-12-31 |
| 2 years earlier | $492.05M Ended 2023-12-31 | $241.62M Ended 2023-12-31 | $159.01M Ended 2023-12-31 | $130.38M Ended 2023-12-31 |
| 3 years earlier | $454.27M Ended 2022-12-31 | $93.46M Ended 2022-12-31 | $138.58M Ended 2022-12-31 | $115.38M Ended 2022-12-31 |
| 4 years earlier | $357.56M Ended 2021-12-31 | $30.26M Ended 2021-12-31 | $127.36M Ended 2021-12-31 | $102.60M Ended 2021-12-31 |